All In MedTech

Device Trial Radar · NCT03390504

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations

A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 629 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

629

Actual

Start

Mar 23, 2018

Primary completion

Apr 15, 2024

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCNot on our public-company list
Sponsor type
Industry
First posted
Jan 4, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer harboring selected fibroblast growth factor receptor (FGFR) aberrations who have progressed after 1 or 2 prior treatments, at least 1 of which includes an anti-programmed death ligand 1(PD-\[L\]1) agent (cohort 1) or 1 prior treatment not containing an anti-PD-(L) 1 agent (cohort 2).

Conditions

  • Urothelial Cancer

Interventions

  • ErdafitinibDrug

    Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.

  • VinflunineDrug

    Participants will receive vinflunine 320 mg/m\^2 as a 20-minute intravenous infusion.

  • DocetaxelDrug

    Participants will receive docetaxel 75 mg/m\^2 as a 1 hour intravenous infusion.

  • PembrolizumabDrug

    Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion.

  • Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)Device

    FGFRi CTA will be used to determine molecular eligibility.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From randomization (3 days prior to Cycle 1 Day 1) until death due to any cause (maximum up to 51.7 months)

Locations

345 sites in 27 countries. Site status is shown where the registry gives one.

  • Alaska Urological Institute dba Alaska Clinical Research Center

    Anchorage, Alaska

  • University of Calif Davis Medical Center

    Sacramento, California

  • St. Helena Hospital - Martin-O'Neil Cancer Center

    St. Helena, California

342 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.